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14871.6%; p ¼ 0.0003) as the result of heart failure with
congestive symptoms.
Our study is the ﬁrst comparing long-term
arrhythmia control among patients with HCM and a
non-affected cohort. We found that the efﬁcacy of AF
ablation is signiﬁcantly lower compared with non-
affected patients, irrespective of the number of pro-
cedures or use of AADs (3). In fact, these are
frequently required. Potential explanations include
anatomic variations in atrial thickness in patients
with HCM as well as different AF substrate and non-
PV triggers. In this study, re-isolation of all chroni-
cally reconnected PVs did not improve arrhythmia
control in patients with HCM to the same extent as
that in non-affected subjects. Our results indicate
that AF ablation is safe in the HCM population,
although it can be associated with signiﬁcant post-
procedural volume retention and pulmonary edema
requiring treatment. When present, LV outﬂow
obstruction is a strong predictor of recurrence.Fernando M. Contreras-Valdes, MD
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Mark E. Josephson, MD
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Platelets Interplay
Between Pneumonia and
Cardiovascular EventsEstablishing a Link?We read with interest the study by Cangemi et al. (1)
entitled “Platelet Activation Is Associated WithMyocardial Infarction in Patients With Pneumonia.”
The authors aimed to shed light on the role of platelet
activation in hospitalized patients with community-
acquired pneumonia (CAP) and myocardial infarc-
tion (MI). Although the ﬁndings of the present study
were also discussed in a well-written editorial by
Santos-Gallego and Badimon (2), we believe that
several issues need to be highlighted and further
clariﬁed in this ﬁeld.
First, both Cangemi et al. (1) and Santos-Gallego
and Badimon (2) support the pathophysiological
link between pneumonia and acute cardiovascular
events with data from the long-lasting infection
hypothesis that implicated microorganisms in
atherosclerosis. It should be noted, however, that no
clear proof of this hypothesis exists, especially after
the failure of antibiotic trials (3). Of note, inﬂuenza
viruses that are mentioned as an example of this
link in both papers account for only 11% of CAP in
hospitalized patients (4).
Furthermore, hospitalized patients with CAP are
characterized by an increased rate of comorbidities
compared with patients not requiring hospitalization.
Comorbidities, such as cardiovascular and cerebro-
vascular disease, diabetes, hypertension, renal fail-
ure, chronic obstructive pulmonary disease, and
peripheral arterial disease, that were present in the
study’s population are well-known entities with
increased platelet reactivity and already established
atherosclerotic alterations (5). Therefore, enhanced
platelet reactivity was probably evident before the
CAP diagnosis in these patients. This hypothesis is
supported by the ﬁnding that higher soluble P-selec-
tin levels were also detected in patients with isolated
increased troponin, but without MI, that were char-
acterized by a higher prevalence of comorbidities.
This result could be explained by the fact that
P-selectin, apart from being a marker of increased
platelet activation through platelet adhesion to
monocytes, also initiates a series of functional re-
sponses implicated in the pathogenesis of athero-
sclerosis, such as transfer of tissue factor to
monocytes, ﬁbrin deposition to growing thrombus,
and superoxide anion and cytokines production by
leukocyte. In that way, P-selectin mediates impor-
tantly the inﬂammatory process of atherosclerosis
and high serum levels of this molecule indicate also
an enhanced atherosclerotic burden that these pa-
tients most likely exhibit as a result of their comor-
bidities. The same applies for CD40L, which induces
the production of chemokines and expression of
adhesion molecules by endothelial cells, thereby
initiating an inﬂammatory response at sites of
vascular injury. Thus, the lack of data on platelet
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1488activation prior to CAP should be considered as a
signiﬁcant limitation of the study that possibly con-
founds its results.
In addition, the editorial by Santos-Gallego and
Badimon (2) raises an important question regarding
the role of platelet aggregation as a risk factor or a
risk marker in these entities. However, platelet
aggregation was not assessed in the present study,
which utilized only soluble markers of platelet
reactivity Platelet activation is an ongoing and
continuous process that is better represented by
ex vivo markers, such as homotypic and heterotypic
platelet aggregation. The gold standard method for
estimation of heterotypic platelet aggregation is
considered the measurement of monocyte-platelet
aggregates (MPA) assessed by ﬂow cytometry. MPA
have been proven a robust and reproducible in vivo
marker of platelet activation (5), even in the clinical
setting (5), and could have been used in order to
assess more accurately the extend of platelet reac-
tivity and to understand the role of platelet func-
tion, and more than that, the role of antiplatelet
therapy.
In conclusion, a number of factors should be taken
into consideration before establishing a connection
between CAP, platelet activation, and MI. Platelets’
pathophysiological interplay between inﬂammation
and thrombosis suggested by in vitro studies needs
to be further investigated in well-designed clinical
studies with robust platelet activation markers.Eleni Gavriilaki, MD, MSc
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Myocardial Infarction in
Patients With PneumoniaAre Statins the Answer?In this population-based cohort study, Cangemi et al.
(1) found that increased platelet activation and
thromboxane overproduction was associated with
myocardial infarction in patients with pneumonia.
Moreover, they also suggested that aspirin alone was
insufﬁcient to inhibit thromboxane production.
Although, the study is observational in nature, it adds
to already accumulated evidence that suggests
increased cardiovascular events with infection and
sepsis (2). Statins with their anti-inﬂammatory and
antithrombotic effects may play a role in the treatment
of pneumonia and prevent associated cardiovascular
complications. Statins have been shown, not only to
inhibit thromboxane synthesis (3), but to also do so in
case of incomplete inhibition by aspirin (4). Statins
also decrease P-selectin and soluble CD40 ligand, both
of which play a role in atherosclerosis and consequent
cardiovascular events. Epidemiological evidence has
shown a beneﬁcial effect in the treatment of pneu-
monia (5). However, the available evidence is weak
because it is based on observational design. Given the
biological plausibility of the association, randomized
controlled trials are needed to deﬁne the role of statins
in the treatment of pneumonia and its associated
cardiovascular complications.*Abdur Rahman Khan, MD
Aref A. Bin Abdulhak, MD
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